Neu-P11, a novel melatonin receptor agonist, could improve the features of type-2 diabetes mellitus in rats

CONCLUSION: Melatonin and its receptor Neu-P11 can reduce blood glucose level, enhance humoral and cellular immunity, inhibit microglia activation and inflammation, and repair islets β cell function, improve the characterization of T2DM related diseases.PMID:34647606 | DOI:10.5603/EP.a2021.0084

Source: Endokrynologia Polska - October 14, 2021 Category: Endocrinology Authors: Xiuping Li Juan He Xing Li Yuxian Li Yang Zhou Shichang Cai Source Type: research